Globally recognized as Objective Testing to Support Asthma Evaluation

Accurate, evidence-based solutions for evaluating airway hyperresponsiveness (AHR) and tracking bronchial inflammation. Built for modern clinical workflows and fully compliant with ATS/ERS guidelines.

For Providers
For Laboratories
For Patients
Vivatmo pro logo

Vivatmo Pro (FeNO Monitoring Device)

  • FeNO monitoring device - a marker associated with type 2 airway inflammation¹
  • Assess current level of airway inflammation and aids evaluation of response to anti-inflammatory therapy, as an adjunct to established clinical and laboratory assessment²
  • High-precision Bosch sensor technology
  • An intuitive and maintenance-free point-of-care device for professional use
  • FDA cleared 510(k)²
Learn More

Provocholine®  (methacholine chloride)

  • To evaluate the level of airway hyperresponsiveness
  • A negative test result helps exclude asthma when symptoms are current or recent³
  • Methacholine Challenge testing is recommended by 2017 ERS/ATS Technical standards on bronchial challenge testing⁴
  • FDA and Health Canada approved
Learn More
Is it Asthma? Clinical studies have shown that up to 33% of patients did not have asthma when objectively assessed

The Cost of an Incorrect Diagnosis

$

Ineffective treatments

$

Inappropriate medication

$

Poor quality of life

$

Poor symptom control

$

Impact on work and school performance

  • What is FeNO testing?

Earn Respiratory Continuing Education Credits On-Demand

Stay up to date with the latest ATS/ERS guidelines and diagnostic best practices on your own schedule. Our AARC-approved continuing education courses provide convenient, high-value learning for modern clinical workflows

$

AARC-Approved Continuing Education Units (CRCE®)

$

100% On-Demand & Self-Paced Learning

$

Focused on Bronchial Challenge Testing & FeNO Diagnostics

Explore On-Demand CRCE Courses

Claims, Billing & Reimbursement Support

Our dedicated support desk provides direct line assistance for all administrative billing and claims inquiries.

Direct Support Line

866-369-9290

}

Desk Hours

Mon-Fri, 8:30 AM - 6:00 PM EST

Support Inbox

methapharm@thepinnaclehealthgroup.com

References

  1. Lommatzsch M, et al. Eosinophils in asthma phenotypes: perpetrators or guilty by association? Lancet Respir Med. 2025;13(1):78–91.
  2. U.S. Food and Drug Administration. Vivatmo® Pro 510(k) Premarket Notification (K182708). Robert Bosch GmbH.
  3. Satia I, Inman M, Davis BE. Methacholine Challenge: Physiology, Methodology, and Clinical Interpretation. Clin Chest Med. 2025;46(3):437–452.
  4. Coates AL, Wanger J, Cockcroft DW, et al. ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. Eur Respir J. 2017;49(5):1601526.
  5. Aaron SD, Vandemheen KL, FitzGerald JM, et al. Reevaluation of diagnosis in adults with physician-diagnosed asthma. JAMA. 2017;317(3):269–279.